No correlation between PNPLA3 rs738409 genotype and fatty liver and hepatic cirrhosis in Japanese patients with HCV

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Nakamura, Masato ^a   Kanda, Tatsuo ^a   Nakamoto, Shingo ^a   Miyamura, Tatsuo ^a   Jiang, Xia ^a   Wu, Shuang ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; TOLL LIKE RECEPTOR 4;

ADULT; ALLELE; ARTICLE; ASPARTATE AMINOTRANSFERASE PLATELET RATIO INDEX; BODY MASS; CONTROLLED STUDY; ECHOGRAPHY; FATTY LIVER; FEMALE; GENE; GENOTYPE; HEPATITIS C; HUMAN; JAPANESE; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING GENE; PNPLA3 GENE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; FATTY LIVER; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIPASE; LIVER CIRRHOSIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84892591294     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0081312     Document Type: Article

References (53)

1. Lavanchy D (2011) Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 17: 107-115. doi: 10.1111/j.1469-0691.2010.03432.x. PubMed: 21091831.
2. Bacon BR, Khalid O (2011) New therapies for hepatitis C virus infection. MO Med 108: 255-259. PubMed: 21905441.
3. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, et al. (1990) Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A 87: 6547-6549. PubMed: 2168552.
4. Di Bisceglie AM (1997) Hepatitis C and hepatocellular carcinoma. Hepatology 26(3 Suppl 1): 34S-38S. PubMed: 9305661.
5. Hu KQ, Kyulo NL, Esrailian E, Thompson K, Chase R, et al. (2004) Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol 40: 147-154. PubMed: 14672626.
6. Harrison SA, Brunt EM, Qazi R, Oliver DA, Neuschwander-Tetri BA, et al. (2005) Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 3: 604-609. PubMed: 15952103.
7. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, et al. (1997) Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 78: 1527-1531. PubMed: 9225025.
8. Nishina S, Korenaga M, Hidaka I, Shinozaki A, Sakai A, et al. (2010) Hepatitis C virus protein and iron overload induce hepatic steatosis through the unfolded protein response in mice. Liver Int 30: 683-692. doi: 10.1111/j.1478-3231.2010.02210.x. PubMed: 20214734.
9. Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, et al. (2007) The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 9: 1089-1097. PubMed: 17721513.
10. Sanyal AJ (2011) NASH: a global health problem. Hepatol Res 41: 670-674. doi: 10.1111/j.1872-034X.2011.00824.x. PubMed: 21711426.
11. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, et al. (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40: 1461-1465. doi: 10.1038/ng.257. PubMed: 18820647.
12. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ, et al. (2010) The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 52: 894-903. doi: 10.1002/hep.23759. PMID: 20684021.
13. Kotronen A, Johansson LE, Johansson LM, Roos C, Westerbacka J, et al. (2009) A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 52: 1056-1060. doi: 10.1007/s00125-009-1285-z. PubMed: 19224197.
14. Romeo S, Sentinelli F, Dash S, Yeo GS, Savage DB, et al. (2010) Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent. Int J Obes (Lond) 34: 190-194. doi: 10.1038/ijo.2009.216. PMID: 19844213.
15. He S, McPhaul C, Li JZ, Garuti R, Kinch L, et al. (2010) A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 285: 6706-6715. doi: 10.1074/jbc.M109.064501. PubMed: 20034933.
16. Wang AP, Migita K, Ito M, Takii Y, Daikoku M, et al. (2005) Hepatic expression of toll-like receptor 4 in primary biliary cirrhosis. J Autoimmun 25: 85-91. PubMed: 16006099.
17. Tamura R, Kanda T, Imazeki F, Wu S, Nakamoto S, et al. (2011) Hepatitis C Virus nonstructural 5A protein inhibits lipopolysaccharide-mediated apoptosis of hepatocytes by decreasing expression of Toll-like receptor 4. J Infect Dis 204: 793-801. doi: 10.1093/infdis/jir381. PubMed: 21844306.
18. Jiang X, Kanda T, Tanaka T, Wu S, Nakamoto S, et al. (2013) Lipopolysaccharide blocks induction of unfolded protein response in human hepatoma cell lines. Immunol Lett 152: 8-15. doi: 10.1016/j.imlet.2013.03.006. PubMed: 23578665.
19. Huang H, Shiffman ML, Cheung RC, Layden TJ, Friedman S, et al. (2006) Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 130: 1679-1687. PubMed: 16697732.
20. Lorenz E, Mira JP, Frees KL, Schwartz DA (2002) Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. Arch Intern Med 162: 1028-1032. PubMed: 11996613.
21. Agnese DM, Calvano JE, Hahm SJ, Coyle SM, Corbett SA, et al. (2002) Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 186: 1522-1525. PubMed: 12404174.
22. Guo J, Loke J, Zheng F, Hong F, Yea S, et al. (2009) Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology 49: 960-968. doi: 10.1002/hep.22697. PubMed: 19085953.
23. Li Y, Chang M, Abar O, Garcia V, Rowland C, et al. (2009) Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection. J Hepatol 51: 750-757. doi: 10.1016/j.jhep.2009.04.027. PubMed: 19586676.
24. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109. doi: 10.1038/ng.449. PubMed: 19749757.
25. Nakamoto S, Kanda T, Imazeki F, Wu S, Arai M, et al. (2011) Simple assay based on restriction fragment length polymorphism associated with IL28B in chronic hepatitis C patients. Scand J Gastroenterol 46: 955-961. doi: 10.3109/00365521.2011.574731. PubMed: 21529139.
26. Tillmann HL, Patel K, Muir AJ, Guy CD, Li JH, et al. (2011) Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol 55: 1195-1200. doi: 10.1016/j.jhep.2011.03. 015. PubMed: 21703198.
27. Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, et al. (2011) IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol 54: 716-722. doi: 10.1016/j.jhep.2010.07.019. PubMed: 21146242.
28. Hwang SJ, Lee SD (2011) Hepatic steatosis and hepatitis C: Still unhappy bedfellows? J Gastroenterol Hepatol 26 Suppl 1: 96-101. doi: 10.1111/j.1440-1746.2010.06542.x. PubMed: 21199519.
29. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Malé PJ, et al. (2000) Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 33: 106-115. PubMed: 10905593.
30. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, et al. (2006) Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 130: 1636-1642. PubMed: 16697727.
31. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, et al. (2003) Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38: 75-85. PubMed: 12829989.
32. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, et al. (2004) The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004 40: 484-490. PubMed: 15123364.
33. Sookoian S, Pirola CJ (2011) Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 53: 1883-1894. doi: 10.1002/hep.24283. PubMed: 21381068.
34. Hotta K, Yoneda M, Hyogo H, Ochi H, Mizusawa S, et al. (2010) Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. BMC Med Genet 11:172. doi: 10.1186/1471-2350-11-172. PubMed: 21176169.
35. Kawaguchi T, Sumida Y, Umemura A, Matsuo K, Takahashi M, et al. (2012) Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS One 7: e38322. doi: 10.1371/journal.pone.0038322. PubMed: 22719876.
36. Kitamoto T, Kitamoto A, Yoneda M, Hyogo H, Ochi H, et al. (2013) Genomewide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Hum Genet 132: 783-792. doi: 10.1007/s00439-013-1294-3. PubMed: 23535911.
37. Kanda T, Yokosuka O, Suzuki Y (2005) Prolonged hepatitis caused by cytomegalovirus and non-alcoholic steatohepatitis in 16-year-old obese boy. Eur J Pediatr 164: 212-215. PubMed: 15682313.
38. Kanda T, Yokosuka O, Hiraide A, Kojima H, Honda A, et al. (2005) Prevalence of obesity in patients with acute hepatitis; is severe obesity a risk factor for fulminant hepatitis in Japan? Hepatogastroenterology 52: 180-182. PubMed: 15783024.
39. Kanda T, Yokosuka O, Imazeki F, Hirasawa Y, Ikeuchi T, et al. (2007) Body mass index in Japanese patients with autoimmune liver disease: overweight patients with primary biliary cirrhosis tend to be asymptomatic. Hepatogastroenterology 54: 1758-1760. PubMed: 18019712.
40. Valenti L, Rumi M, Galmozzi E, Aghemo A, Del Menico B, et al. (2011) Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology 53: 791-799. doi: 10.1002/hep.24123. PubMed: 21319195.
41. Trépo E, Pradat P, Potthoff A, Momozawa Y, Quertinmont E, et al. (2011) Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology 54: 60-69. doi: 10.1002/hep.24350. PubMed: 21488075.
42. Kanayama Y, Kamiyama N, Maruyama K, Sumino Y (2013) Real-time ultrasound attenuation imaging of diffuse fatty liver disease. Ultrasound Med Biol 39: 692-705. doi: 10.1016/j.ultrasmedbio.2012.10.021. PubMed: 23415286.
43. Kondo F, Ebara M, Sugiura N, Wada K, Kita K, et al. (1990) Histological features and clinical course of large regenerative nodules: evaluation of their precancerous potentiality. Hepatology 12(3 Pt 1): 592-598. PMID: 1698171.
44. Gaia S, Carenzi S, Barilli AL, Bugianesi E, Smedile A, et al. (2011) Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol 54: 64-71. doi: 10.1016/j.jhep.2010.06.022. PubMed: 20932598.
45. Brent EM (2004) Nonalcoholic steatohepatitis. Semin Liver Dis 24: 3-20. PubMed: 15085483.
46. Yoshioka Y, Hashimoto E, Yatsuji S, Kaneda H, Taniai M, et al. (2004) Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burn-out NASH. J Gastroenterol 39: 1215-1218. PubMed: 15622489.
47. Tanaka T, Tsukiyama-Kohara K, Yamaguchi K, Yagi S, Tanaka S, et al. (1994) Significance of specific antibody assay for genotyping of hepatitis C virus. Hepatology 19: 1347-1353. PMID: 7514558.
48. Kanda T, Imazeki F, Yokosuka O (2010) New antiviral therapies for chronic hepatitis C. Hepatol Int 4: 548-561. Doi: 10.1007/s12072-010-9193-3. PubMed: 21063477.
49. Wu S, Kanda T, Nakamoto S, Jiang X, Miyamura T, et al. (2013) Prevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: ultra-deep sequencing analysis of HCV NS5B genotype-specific region. PLoS One 8: e73615. doi:10.1371/journal.pone.0073615. PubMed: 24069214.
50. Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, et al. (2005) Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42: 962-793. PubMed: 16149085.
51. Miyamura T, Kanda T, Nakamoto S, Wu S, Fujiwara K, et al. (2011) Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients. PLoS One 6: e28617. doi: 10.1371/journal.pone.0028617. PMID: 22174846.
52. Miyamura T, Kanda T, Nakamoto S, Wu S, Jiang X, et al. (2012) Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin. Viruses 4: 1264-1278. PMID: 23012624.
53. Nakamura M, Kanda T, Miyamura T, Wu S, Nakamoto S, et al. (2013) Alanine aminotransferase elevation during peginterferon alpha-2a or alpha-2b plus ribavirin treatment. Int J Med Sci 10: 1015-1021. doi: 10.7150/ijms.6402. PMID: 23801888.